Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 234 Shares

Moderna, Inc. (NASDAQ:MRNAGet Rating) President Stephen Hoge sold 234 shares of the firm’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $133.71, for a total transaction of $31,288.14. Following the transaction, the president now directly owns 1,622,820 shares of the company’s stock, valued at $216,987,262.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Stephen Hoge also recently made the following trade(s):

  • On Tuesday, May 3rd, Stephen Hoge sold 10,000 shares of Moderna stock. The stock was sold at an average price of $141.93, for a total transaction of $1,419,300.00.
  • On Monday, April 25th, Stephen Hoge sold 20,000 shares of Moderna stock. The stock was sold at an average price of $143.22, for a total transaction of $2,864,400.00.
  • On Tuesday, April 12th, Stephen Hoge sold 5,000 shares of Moderna stock. The shares were sold at an average price of $159.00, for a total transaction of $795,000.00.
  • On Monday, April 4th, Stephen Hoge sold 20,000 shares of Moderna stock. The shares were sold at an average price of $177.27, for a total transaction of $3,545,400.00.
  • On Thursday, March 24th, Stephen Hoge sold 5,000 shares of Moderna stock. The shares were sold at an average price of $175.52, for a total transaction of $877,600.00.
  • On Friday, March 18th, Stephen Hoge sold 7,541 shares of Moderna stock. The shares were sold at an average price of $171.67, for a total transaction of $1,294,563.47.
  • On Monday, February 14th, Stephen Hoge sold 20,000 shares of Moderna stock. The shares were sold at an average price of $157.71, for a total transaction of $3,154,200.00.
  • On Thursday, February 10th, Stephen Hoge sold 894 shares of Moderna stock. The shares were sold at an average price of $158.89, for a total transaction of $142,047.66.

Shares of NASDAQ:MRNA opened at $137.91 on Friday. Moderna, Inc. has a one year low of $119.01 and a one year high of $497.49. The company has a 50 day moving average of $155.48 and a 200-day moving average of $201.21. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.77 and a quick ratio of 1.56. The stock has a market cap of $54.86 billion, a price-to-earnings ratio of 4.05, a P/E/G ratio of 0.75 and a beta of 1.70.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported $8.58 EPS for the quarter, topping the consensus estimate of $6.16 by $2.42. Moderna had a net margin of 64.77% and a return on equity of 121.86%. The company had revenue of $6.07 billion during the quarter, compared to analysts’ expectations of $4.43 billion. During the same quarter in the previous year, the company earned $2.84 EPS. Moderna’s revenue was up 213.2% on a year-over-year basis. Equities research analysts anticipate that Moderna, Inc. will post 27.22 earnings per share for the current year.

MRNA has been the subject of several analyst reports. SVB Leerink cut their price target on shares of Moderna from $81.00 to $80.00 and set an “underperform” rating for the company in a report on Friday, March 25th. TheStreet cut shares of Moderna from a “b-” rating to a “c+” rating in a research report on Thursday, February 24th. Jefferies Financial Group lowered their price objective on shares of Moderna from $200.00 to $170.00 in a research report on Friday, February 25th. Morgan Stanley raised their price objective on shares of Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. Finally, UBS Group began coverage on shares of Moderna in a research report on Friday, January 21st. They issued a “neutral” rating and a $221.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $246.92.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Stokes Family Office LLC grew its holdings in Moderna by 8.2% during the third quarter. Stokes Family Office LLC now owns 1,162 shares of the company’s stock valued at $447,000 after purchasing an additional 88 shares during the period. Horizon Investments LLC acquired a new position in Moderna during the third quarter valued at approximately $2,137,000. Arrowstreet Capital Limited Partnership acquired a new position in Moderna during the third quarter valued at approximately $159,563,000. LPL Financial LLC grew its holdings in Moderna by 19.3% during the third quarter. LPL Financial LLC now owns 150,061 shares of the company’s stock valued at $57,753,000 after purchasing an additional 24,239 shares during the period. Finally, First Republic Investment Management Inc. grew its holdings in Moderna by 10.9% during the third quarter. First Republic Investment Management Inc. now owns 98,867 shares of the company’s stock valued at $38,050,000 after purchasing an additional 9,679 shares during the period. Hedge funds and other institutional investors own 61.20% of the company’s stock.

Moderna Company Profile (Get Rating)

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.

See Also

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.